NASDAQ:VOR 11 November 2025

Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors

Vor Biopharma shares jumped 31% to close at $10.95 on December 9, 2025, with trading volume exceeding 26 million shares. The surge followed JPMorgan’s new “Overweight” rating and $43 price target, positive late-stage data for telitacicept, and news the board repriced 5.2 million employee stock options to $8.18.

9 December 2025

NASDAQ:VOR·Stock Market

Vor Biopharma (VOR) Prices $100M Stock Offering at $10; Shares Slide as Investors Weigh Dilution — Nov. 11, 2025

Vor Biopharma priced 10 million new shares at $10 each for $100 million in expected gross proceeds, with underwriters able to buy up to 1.5 million more. Shares fell from $13.03 pre-market to near $10 by mid-morning Tuesday. The offering follows positive Phase 3 IgA nephropathy data from partner RemeGen. The deal is set to close around Nov. 12, 2025, with J.P. Morgan, Jefferies, Citigroup, and TD Cowen as joint bookrunners.

11 November 2025

NASDAQ:VOR·Stock Market

Union Pacific Stock Seen Undervalued Amid Recent Price Drop
March 20, 2026, 2:10 PM EDT. Union Pacific (ticker: UNP) shares dropped roughly 11% over the past month, now trading near $234. Despite this short-term weakness, the railroad operator maintains positive returns of 1% year-to-date and over 20% across five years. A discounted cash flow (DCF) analysis estimates an intrinsic value around $313 per share, indicating the stock trades about 25% below its cash flow-based valuation, suggesting undervaluation. The price-to-earnings (P/E) metric offers another lens but is secondary to DCF in this review. Investors should weigh recent volatility against Union Pacific's strong long-term fundamentals and sector dynamics before deciding whether current weakness presents a buying opportunity.